AUPO434196A0 - An improved therapeutic - Google Patents

An improved therapeutic

Info

Publication number
AUPO434196A0
AUPO434196A0 AUPO4341A AUPO434196A AUPO434196A0 AU PO434196 A0 AUPO434196 A0 AU PO434196A0 AU PO4341 A AUPO4341 A AU PO4341A AU PO434196 A AUPO434196 A AU PO434196A AU PO434196 A0 AUPO434196 A0 AU PO434196A0
Authority
AU
Australia
Prior art keywords
improved therapeutic
therapeutic
improved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPO4341A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
State of Queensland Department of Health
Original Assignee
CROWN IN RIGHT OF QUEE
State of Queensland Department of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CROWN IN RIGHT OF QUEE, State of Queensland Department of Health filed Critical CROWN IN RIGHT OF QUEE
Priority to AUPO4341A priority Critical patent/AUPO434196A0/en
Publication of AUPO434196A0 publication Critical patent/AUPO434196A0/en
Priority to PCT/AU1997/000884 priority patent/WO1998028004A1/en
Priority to AU78716/98A priority patent/AU7871698A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AUPO4341A 1996-12-24 1996-12-24 An improved therapeutic Abandoned AUPO434196A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPO4341A AUPO434196A0 (en) 1996-12-24 1996-12-24 An improved therapeutic
PCT/AU1997/000884 WO1998028004A1 (en) 1996-12-24 1997-12-24 Hepatitis delta particle containing a fusion protein immunogen
AU78716/98A AU7871698A (en) 1996-12-24 1997-12-24 Hepatitis delta particle containing a fusion protein immunogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO4341A AUPO434196A0 (en) 1996-12-24 1996-12-24 An improved therapeutic

Publications (1)

Publication Number Publication Date
AUPO434196A0 true AUPO434196A0 (en) 1997-01-23

Family

ID=3798649

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPO4341A Abandoned AUPO434196A0 (en) 1996-12-24 1996-12-24 An improved therapeutic

Country Status (2)

Country Link
AU (1) AUPO434196A0 (en)
WO (1) WO1998028004A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP706098A0 (en) * 1998-11-11 1998-12-03 North Western Health Care Network Biological compositions, components thereof and uses therefor
WO2001002551A2 (en) * 1999-06-30 2001-01-11 Evotec Oai Ag Virus like particles, preparation and use in screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
AUPQ912000A0 (en) * 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
AU2001276182B2 (en) * 2000-07-31 2006-05-04 Monash University Improved virus like particles based on small envelope protein from hepatitis B (HBsAg-S)
DE60037263T2 (en) * 2000-12-29 2008-10-09 Evotec Ag Virus-like particles, their preparation and their use in pharmaceutical screening and functional genome applications
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
AU2015210336B2 (en) * 2010-08-17 2017-05-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
CN103732250A (en) 2011-06-14 2014-04-16 全球免疫股份有限公司 Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
KR102545316B1 (en) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Hepatitis b virus (hbv) irna compositions and methods of use thereof
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
JP7625512B2 (en) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225347A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors

Also Published As

Publication number Publication date
WO1998028004A1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
AUPO203996A0 (en) Therapeutic uses
AU4787697A (en) Therapeutic gene
AU4040197A (en) Microturbomachinery
AU3387997A (en) Autonotification
AU2845197A (en) Cycloalkano-pyridines
AU4945197A (en) Aminothiophenecarboxamides
AU4013397A (en) Arylalkanoylpyridazines
AU2684197A (en) Handleset
AU4176997A (en) 3-alkyl-3-phenyl-piperidines
AU4218597A (en) Superseat
AUPO434196A0 (en) An improved therapeutic
AU2090897A (en) Hydroxyhexahydropyridazines
AU3130597A (en) Tristetraprolin
AU5221598A (en) Sweet-toy
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AU2237197A (en) Fishing-lure
AU4332497A (en) Endo-beta-galactosidase
AU1900097A (en) Cremators
AU4582597A (en) Therapeutic proteins
AU3557397A (en) Double-tau-profile
AU1597197A (en) Thienoquinolines
AU5002897A (en) Gripper-accumulator
AU5330198A (en) Therapeutic compounds
AU1643797A (en) Repeater-system
AU5016496A (en) Y-spring